Immune cells can detect cancer-causing genetic mutations when mutated peptides known as neoantigens are presented on the surface of tumor cells. However, tumor cells may evade immune cell detection by a variety of mechanisms involving the presentation and recognition of those neoantigens. Because the protein complexes responsible for displaying these peptides on the cell surface can vary widely from patient to patient, studying these mechanisms and developing prognostic and predictive models remains a challenge. In addition, there is often inconsistency among the different clinical assays currently used to identify and understand each cancer patient’s unique pattern of mutations. Researchers in the Baras lab are using the computational power of artificial intelligence to tackle the challenges arising from this complexity. First, they are creating machine-learning algorithms that reconcile differences between clinical test platforms to more accurately understand the characteristics of tumors. Then they will extend their analyses to identify which mutated peptides and protein complexes are most likely to appear on the surface of tumor cells as influenced by the unique genetic make-up of both the tumor and the patient. Once they have achieved this goal, they will use machine learning to predict the ability of immune cells to detect and kill an individual patient’s tumor cells. This artificial intelligence-based approach promises to be useful in accurately predicting prognosis and forecasting how patients will respond to anti-cancer therapies, especially those that harness the immune system.